According to the Zhitong Finance App, Kangfang Biology-B (09926) announced that on September 20, 2022, Tianqing Kangfang (a subsidiary of the company) signed a general procurement agreement for materials and services with Chia Tai Tianqing for the treatment of hepatocellular carcinoma. Based on this, Tianqing Kangfang agreed to purchase and Chia Da Tianqing agreed to provide clinical materials and clinical services.
According to the general procurement agreement for materials and services, Tianqing Kangfang will procure and Chia Tai Tianqing will provide: certain drugs and clinical pharmaceutical materials (including but not limited to reagents and control drugs); and certain clinical trial services for the phase III registration trial relating to the treatment of hepatocellular carcinoma with empiperidine.